<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.93047</article-id><article-id pub-id-type="publisher-id">ACM-29240</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190300000_53712104.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肝癌移植术后复发相关标志物的研究进展
  Molecular Markers and Recurrence of Hepatocellular Carcinoma after Liver Transplantation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>章</surname><given-names>文燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>树森</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>浙江大学医学院附属第一医院肝胆胰外科，浙江 杭州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>02</month><year>2019</year></pub-date><volume>09</volume><issue>03</issue><fpage>310</fpage><lpage>318</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肝移植是治疗肝细胞肝癌(Hepatocellular carcinoma, HCC)的重要方法，但移植后的HCC复发影响了治疗效果，尽管有严格的纳入标准，但移植术后仍有较高的复发率。随着分子生物学的发展，HCC移植术后复发相关的分子标志物被不断提出并进行分析研究。在这篇综述中，我们重点关注肿瘤标志物和炎症标志物与HCC移植术后的相关性。HCC相关的肿瘤标志物主要有甲胎蛋白(Alpha-fetoprotein, AFP)、脱-γ-羧基凝血酶原(Des-gamma-carboxyprothrombin, DCP)等，相关的炎症标志物主要有C反应蛋白(C-reactive protein, CRP)、中性粒细胞淋巴细胞比值(Neutrophil lymphocyte ratio, NLR)、血小板淋巴细胞比值(Platelet lymphocyte ratio, PLR)等。但这些标志物都存在一定的缺陷，希望能通过更多的多中心的前瞻性研究，找着更好的分子标志物组合，从而更好地预测移植后复发，以希望获得更好的移植效果。
    Liver transplantation is a potentially curative treatment for hepatocellular carcinoma (HCC). But, the recurrence of HCC after transplantation has seriously affected the treatment effect. Despite stringent selection criteria, recurrence occurs in a high proportion of patients transplanted for HCC. With the development of molecular biology, there are more and more molecular markers related to the recurrence after liver transplantation. In this review, we focus on the tumor markers and inflammatory markers. Tumor markers mainly include Alpha-fetoprotein (AFP), Des-gamma-carboxyprothrombin (DCP), etc. Inflammatory markers include C-reactive protein (CRP), Neutrophil lymphocyte ratio (NLR) and Platelet lymphocyte ratio (PLR), etc. However, taking into account the limitations of these markers, multicenter prospective studies are essential to find a better combination of molecular markers, which means better prediction of recurrence and better transplant treatment effect. 
  
 
</p></abstract><kwd-group><kwd>肝细胞肝癌，肝移植，复发，分子标志物，综述, Hepatocellular Carcinoma</kwd><kwd> Liver Transplantation</kwd><kwd> Recurrence</kwd><kwd> Molecular Markers</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肝癌移植术后复发相关标志物的 研究进展<sup> </sup></title><p>章文燕，郑树森</p><p>浙江大学医学院附属第一医院肝胆胰外科，浙江 杭州</p><p><img src="//html.hanspub.org/file/22-1570861x1_hanspub.png" /></p><p>收稿日期：2019年2月21日；录用日期：2019年3月5日；发布日期：2019年3月14日</p><disp-formula id="hanspub.29240-formula65"><graphic xlink:href="//html.hanspub.org/file/22-1570861x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>肝移植是治疗肝细胞肝癌(Hepatocellular carcinoma, HCC)的重要方法，但移植后的HCC复发影响了治疗效果，尽管有严格的纳入标准，但移植术后仍有较高的复发率。随着分子生物学的发展，HCC移植术后复发相关的分子标志物被不断提出并进行分析研究。在这篇综述中，我们重点关注肿瘤标志物和炎症标志物与HCC移植术后的相关性。HCC相关的肿瘤标志物主要有甲胎蛋白(Alpha-fetoprotein, AFP)、脱-γ-羧基凝血酶原(Des-gamma-carboxyprothrombin, DCP)等，相关的炎症标志物主要有C反应蛋白(C-reactive protein, CRP)、中性粒细胞淋巴细胞比值(Neutrophil lymphocyte ratio, NLR)、血小板淋巴细胞比值(Platelet lymphocyte ratio, PLR)等。但这些标志物都存在一定的缺陷，希望能通过更多的多中心的前瞻性研究，找着更好的分子标志物组合，从而更好地预测移植后复发，以希望获得更好的移植效果。</p><p>关键词 :肝细胞肝癌，肝移植，复发，分子标志物，综述</p><disp-formula id="hanspub.29240-formula66"><graphic xlink:href="//html.hanspub.org/file/22-1570861x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1570861x7_hanspub.png" /> <img src="//html.hanspub.org/file/22-1570861x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>原发性肝癌是世界上最常见的恶性肿瘤之一，也是死亡率极高的全球疾病 [<xref ref-type="bibr" rid="hanspub.29240-ref1">1</xref>]。据最新的国家癌症中心统计数据显示 [<xref ref-type="bibr" rid="hanspub.29240-ref2">2</xref>]，我国2015年原发性肝癌发病率高达26.92/10万，死亡率为23.72/10万，是我国第4常见恶性肿瘤，位居我国恶性肿瘤死亡病因第2位，严重威胁我国人民的生命和健康。病理学上，原发性肝癌主要可以分为肝细胞肝癌(Hepatocellular Carcinoma, HCC)、肝内胆管癌(Intrahepatic Cholangiocarcinoma, ICC)和混合型，其中HCC占到85%~90%以上 [<xref ref-type="bibr" rid="hanspub.29240-ref3">3</xref>]。由于这三种病理类型在发病机制、临床表现及治疗等方面差异较大，因此，本文中主要讨论发病率最高的HCC。</p><p>在我国，大部分HCC患者合并有乙型病毒性肝炎导致的肝硬化，这部分患者的手术切除率往往不是很理想，肝移植是根治HCC的有效方法，特别是对失代偿期肝硬化且不适合手术切除的小肝癌患者 [<xref ref-type="bibr" rid="hanspub.29240-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref4">4</xref>]。肝移植不仅可以完整切除HCC，同时还可以去除肝硬化组织，恢复正常的肝脏功能。HCC患者肝移植后的5年生存率可达50%~81% [<xref ref-type="bibr" rid="hanspub.29240-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref9">9</xref>]，而根治性肝切除术后的5年生存率仅为25%~50% [<xref ref-type="bibr" rid="hanspub.29240-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref11">11</xref>]，肝移植在HCC的治疗中的重要性不言而喻。然而HCC患者移植术后复发问题仍然困扰着所有进行肝移植的患者以及肝移植治疗团队。</p><p>尽管有严格的纳入标准，但HCC患者进行肝移植后的复发率高达6%~18.3% [<xref ref-type="bibr" rid="hanspub.29240-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref14">14</xref>]，也有数据称不同中心HCC肝移植术后5年HCC复发率可达20.0%~57.8% [<xref ref-type="bibr" rid="hanspub.29240-ref15">15</xref>]，HCC复发多见于肺、骨和腹部淋巴结，肝外复发约占50%~70% [<xref ref-type="bibr" rid="hanspub.29240-ref16">16</xref>]，肝内复发比例约为30% [<xref ref-type="bibr" rid="hanspub.29240-ref17">17</xref>]，且多在移植后2年内复发。众所周知，肝移植后肿瘤复发明显减低了移植后生存率，及早发现和治疗移植后HCC复发显得十分重要。因此，一方面，移植后肝癌复发治疗受到极大关注，主要治疗方法包括免疫治疗，靶向药物治疗，手术再次切除，经动脉化疗栓塞术(Trans-arterial chemoembolization, TACE)，射频消融术(Radiofrequency ablation, RFA)，立体定向放射治疗术(Stereotactic body radiation therapy, SBRT)等 [<xref ref-type="bibr" rid="hanspub.29240-ref12">12</xref>]。另一方面，国内外学者均希望提出更有效实用的预测模型，更合理地筛选患者进行肝移植，其中分子标志物是重要研究内容之一。目前已有多种分子标志物被用于HCC患者移植后复发的预测，包括肿瘤标志物，炎症标志物，各种蛋白(如血管内皮生长因子，VEGF)，病毒及载量(如乙肝病毒，HBV)，基因(如P53基因)，液体活检(包括循环肿瘤细胞和无细胞DNA)，循环RNA等。本综述将重点阐述HCC肝移植患者纳入标准及术后复发相关肿瘤标志物和炎症标志物的研究进展。</p></sec><sec id="s4"><title>2. 常用的HCC肝移植患者纳入标准</title><p>为了更合理地利用供肝资源，降低肝移植术后HCC复发率，提高HCC患者的长期生存率，各大移植中心都严格掌握HCC肝移植的适应征。米兰标准 [<xref ref-type="bibr" rid="hanspub.29240-ref18">18</xref>]，USCF标准 [<xref ref-type="bibr" rid="hanspub.29240-ref19">19</xref>] 和杭州标准 [<xref ref-type="bibr" rid="hanspub.29240-ref20">20</xref>] 是最常用的三种HCC肝移植患者纳入标准。此外，2000年Pittsburgh等人改良了TNM分期标准 [<xref ref-type="bibr" rid="hanspub.29240-ref21">21</xref>]，2007年德国学者提出Berlin标准 [<xref ref-type="bibr" rid="hanspub.29240-ref22">22</xref>]，2007年日本学者提出东京5-5标准 [<xref ref-type="bibr" rid="hanspub.29240-ref23">23</xref>]，2008年韩国学者提出Asan标准 [<xref ref-type="bibr" rid="hanspub.29240-ref24">24</xref>]，2009年Mazzaffero等人提出了最多7个(Up-to-seven)标准 [<xref ref-type="bibr" rid="hanspub.29240-ref25">25</xref>] 等。而在国内，除了杭州标准外，还有2009年樊嘉院士团队提出复旦标准 [<xref ref-type="bibr" rid="hanspub.29240-ref26">26</xref>] 和2009年严律南教授团队提出的成都标准 [<xref ref-type="bibr" rid="hanspub.29240-ref27">27</xref>] 等。</p><sec id="s4_1"><title>2.1. 米兰标准</title><p>米兰标准 [<xref ref-type="bibr" rid="hanspub.29240-ref18">18</xref>] 由意大利的Mazzaferro等人在1996年提出，这是最早提出的HCC患者进行肝移植的标准，也是目前使用最为广泛的患者纳入标准 [<xref ref-type="bibr" rid="hanspub.29240-ref28">28</xref>]，1998年起，美国联合网络器官共享(UNOS)将米兰标准作为主要选择标准。米兰标准的主要内容为：① 单个肿瘤直径 ≤ 5 cm或者多发肿瘤不超过3个且最大直径 ≤ 3 cm；② 没有主要血管侵犯，没有淋巴结或肝外转移。该标准大大提高了HCC肝移植的术后生存率，Mazzaferro等报道的48名患者的术后4年生存率和无瘤生存率分别为85%和92% [<xref ref-type="bibr" rid="hanspub.29240-ref18">18</xref>]。随后多个中心的研究也提示符合米兰标准的HCC患者肝移植后具有良好的预后，5年生存率可以高达75%~80% [<xref ref-type="bibr" rid="hanspub.29240-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref29">29</xref>]。</p><p>然而，通过临床实践及总结分析，许多学者认为米兰标准存在局限性，一方面，米兰标准对肿瘤的大小限制过于严苛，许多需要进行肝移植的患者被排除在外，而临床实践证明，这些不符合米兰标准的患者进行肝移植后仍可以获得令人满意的预后 [<xref ref-type="bibr" rid="hanspub.29240-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref32">32</xref>]。另一方面，米兰标准未考虑肿瘤的生物学特征：如组织病理学分级和血清AFP指标等。近年来，越来越多的国际肝移植中心对米兰标准及超过米兰标准的肝移植进行了进一步研究，其中就包括USCF标准和杭州标准的提出。</p></sec><sec id="s4_2"><title>2.2. UCSF标准</title><p>2002年加州大学旧金山分校的研究人员提出了UCSF标准，将HCC肝移植的适应征适当放宽：①单个肿瘤，直径 ≤ 6.5 cm，或肿瘤数目 ≤ 3个，直径最大 ≤ 4.5 cm且肿瘤直径之和 ≤ 8 cm。② 没有主要血管侵犯或肝外转移。Yao等人报道 [<xref ref-type="bibr" rid="hanspub.29240-ref19">19</xref>]，米兰标准和USCF标准的HCC肝移植患者的5年生存率差异没有统计学意义，而且超过UCSF标准的HCC患者移植后5年生存率显著降低。USCF标准明显扩大了HCC肝移植受体范围，而且不影响其总体生存率。我国国家卫计委新发布的原发性肝癌诊疗规范(2017版)提出现阶段肝癌肝移植推荐使用UCSF标准 [<xref ref-type="bibr" rid="hanspub.29240-ref3">3</xref>]。与米兰标准相同的是，USCF也未关注肿瘤的病理学特征或肿瘤标志物等因素。</p></sec><sec id="s4_3"><title>2.3. 杭州标准</title><p>HCC是我国最常见的恶性肿瘤之一，位居死亡病因第2位。使用国际标准选择肝移植受体，将使许多HCC患者失去肝移植机会，因此建立新的HCC肝移植受体纳入标准势在必行。2008年，郑树森院士团体提出了HCC肝移植的杭州标准 [<xref ref-type="bibr" rid="hanspub.29240-ref20">20</xref>] ：① 肿瘤没有主要血管侵犯和肝外转移。② 所有肿瘤结节直径之和 ≤ 8 cm，或所有肿瘤结节直径之和 &gt; 8 cm，但是满足术前AFP(血清甲胎蛋白)水平 &lt; 400 ng/mL，且组织学分级为高、中分化。杭州标准不仅在肿瘤大小限制上超越了米兰标准和UCSF标准，而且首次引入了HCC的组织病理学分级和血清AFP指标，研究结果显示杭州标准和USCF标准的HCC肝移植患者的术后生存率和无瘤生存率差异无统计学意义，但杭州标准的入组HCC患者例数增加了37.5%，安全地扩大了HCC肝移植的受体池。Chen等人研究表明 [<xref ref-type="bibr" rid="hanspub.29240-ref33">33</xref>]，杭州标准的1年、5年生存率分别为92.3%、80.8%，1年、5年无瘤生存率分别为92.3%、76.1%。该研究结果发表后得到了移植界的肯定，杭州的标准也适用于其他国家和地区 [<xref ref-type="bibr" rid="hanspub.29240-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref35">35</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref36">36</xref>]。</p></sec></sec><sec id="s5"><title>3. HCC复发相关肿瘤标志物</title><sec id="s5_1"><title>3.1. 甲胎蛋白(Alpha-Fetoprotein, AFP)</title><p>甲胎蛋白AFP是一种大小为67 kDa的糖蛋白，主要由胎儿肝细胞及卵黄囊合成，在正常成人血清中含量极低，它可以反映HCC的肿瘤分化和血管浸润情况，已被广泛应用于HCC肝移植患者的筛选，最典型的就是杭州标准。此外法国学者提出的AFP模型 [<xref ref-type="bibr" rid="hanspub.29240-ref37">37</xref>] 主要基于肿瘤形态学数据和AFP数据，在米兰标准内，AFP &gt; 1000 ng/mL其复发风险将明显提高(37.7% vs 13.3%)；另一方面，超过米兰标准，但AFP小于100 ng/mL的患者其5年复发率仅为14.4%。该模型被成功应用于法国肝脏分配。另一项研究报告显示总肿瘤体积 ≤ 115 cm<sup>3</sup>和移植后AFP ≤ 400 ng/mL提示低移植后HCC复发风险 [<xref ref-type="bibr" rid="hanspub.29240-ref38">38</xref>]，且进行了多中心前瞻性的验证 [<xref ref-type="bibr" rid="hanspub.29240-ref39">39</xref>]。</p><p>尽管AFP已经被证明是一种有用的肿瘤标志物，但其最佳临界值尚未达成共识，如上述提到的杭州标准的400 ng/mL、AFP模型的1000 ng/mL、日本学者提出的500 ng/mL [<xref ref-type="bibr" rid="hanspub.29240-ref32">32</xref>] 等。此外，AFP的动态变化能更好反映肿瘤生物学行为变化。如果患者术前的每月AFP增加值 &gt; 50 ng/mL [<xref ref-type="bibr" rid="hanspub.29240-ref40">40</xref>]，或者每天AFP增加值 &gt; 0.1 ng/mL [<xref ref-type="bibr" rid="hanspub.29240-ref41">41</xref>]，这些都可能意味着移植预后不佳。</p><p>但AFP也存在不足之处，约80%的小HCC (&lt;2 cm)患者的AFP在正常范围内 [<xref ref-type="bibr" rid="hanspub.29240-ref42">42</xref>]，另一方面，慢性肝病患者的AFP也会有不同程度升高 [<xref ref-type="bibr" rid="hanspub.29240-ref43">43</xref>]，在一些神经退行性疾病中也已描述了AFP水平的增加 [<xref ref-type="bibr" rid="hanspub.29240-ref44">44</xref>]。而且AFP升高常意味着HCC预后不佳，目前，美国肝病研究协会(AASLD) [<xref ref-type="bibr" rid="hanspub.29240-ref45">45</xref>] 、欧洲肝脏研究协会(EASL) [<xref ref-type="bibr" rid="hanspub.29240-ref46">46</xref>] 、美国国家综合癌症网络(NCCN) [<xref ref-type="bibr" rid="hanspub.29240-ref47">47</xref>] 等均已不再推荐AFP作为HCC筛查指标。因此，有学者提出使用AFP异质体——AFP-L3作为新的肿瘤标志物，它被认为是低AFP水平患者的HCC高度特异性标志物，可以更好预测低AFP水平患者的移植术后复发情况 [<xref ref-type="bibr" rid="hanspub.29240-ref48">48</xref>]，这个新的肿瘤标志物需要更多的研究。</p></sec><sec id="s5_2"><title>3.2. 脱-γ-羧基凝血酶原(Des-Gamma-Carboxyprothrombin, DCP)</title><p>Des-γ-羧基凝血酶原DCP，也称为维生素K缺乏或拮抗剂-II诱导产生的蛋白(PIVKA-II)，是由肝脏产生的无功能的凝血酶原形式。正常肝脏中通过维生素K依赖性羧化酶的催化作用将凝血酶原N-末端部分中的谷氨酸残基完全羧化，从而向外周血分泌正常的凝血酶原。而在异常肝细胞中，由于不存在产生这种羧化的维生素K依赖性羧化酶，因此会分泌异常凝血酶原，即DCP。DCP阳性已被证实与HCC的恶性程度相关，DCP阳性的HCC患者的肝内转移和门静脉浸润发生的概率明显增加 [<xref ref-type="bibr" rid="hanspub.29240-ref49">49</xref>]，也更容易术后复发 [<xref ref-type="bibr" rid="hanspub.29240-ref50">50</xref>]。</p><p>日本学者提出了基于DCP的活体肝移植患者纳入标准——京都标准 [<xref ref-type="bibr" rid="hanspub.29240-ref51">51</xref>]，该标准要求肿瘤数目 ≤ 10个，肿瘤直径 ≤ 5 cm，DCP ≤ 400 mAU/mL，符合京都标准但不符合米兰标准的患者也能取得令人满意的生存期和无瘤生存率。</p><p>但DCP更常联合AFP用于HCC肝移植术后复发的预测，AP200 [<xref ref-type="bibr" rid="hanspub.29240-ref52">52</xref>] 标准认为AFP ≤ 200 ng/mL和DCP ≤ 200 AU/mol可提示患者术后复发风险低，Kim等人 [<xref ref-type="bibr" rid="hanspub.29240-ref53">53</xref>] 回顾性分析了77例复发的病例，认为肿瘤大小 &gt; 5 cm，AFP &gt; 150 ng/mL，DCP &gt; 100 maul/mol是HCC肝移植术后复发的独立危险因素。但就目前的相关研究而言，DCP更多应用于活体肝移植，而DCD(公民逝世后器官捐献)肝移植较少。</p></sec><sec id="s5_3"><title>3.3. 其他肿瘤标志物</title><p>除了上述提到的AFP、AFP-L3和DCP，α-L-岩藻糖苷酶(AFU)、糖链抗原19-9 (CA19-9)、癌胚抗原(CEA)等也是HCC相关的肿瘤标志物 [<xref ref-type="bibr" rid="hanspub.29240-ref54">54</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref55">55</xref>]，但它们在HCC肝移植中的作用研究较少，目前它们对移植术后HCC复发的预测作用尚不明确。</p></sec></sec><sec id="s6"><title>4. 炎症标志物</title><sec id="s6_1"><title>4.1. C反应蛋白(C-Reactive Protein, CRP)</title><p>CRP作为急性和慢性炎症的标志物已经获得了显著的临床价值，它由肝细胞合成，且受到白介素-1和白介素-6的调节，它对感染，损伤或恶性肿瘤等都有反应。人们越来越关注CRP在预测恶性肿瘤中的作用 [<xref ref-type="bibr" rid="hanspub.29240-ref56">56</xref>] [<xref ref-type="bibr" rid="hanspub.29240-ref57">57</xref>]，CRP被广泛用于HCC复发转移等相关研究，也被用于移植术后复发的预测。移植术前和术后的CRP水平均具有预测功能，是一种有价值的标志物。An等人 [<xref ref-type="bibr" rid="hanspub.29240-ref58">58</xref>] 在2012年报道了一项85名接受肝移植的HCC患者(绝大多数是接受活体肝移植)的研究，所有患者均具有可用的移植前CRP水平，相关分析表明CRP ≥ 1 mg/dL是患者死亡和肿瘤复发的重要独立危险因素。有趣的是，术前CRP与移植后的生存率和无瘤生存率之间的相关性仅限于米兰标准以外的患者，换句话说，更高风险的人群需要更详细的风险分层，从而得到更安全的移植。</p><p>与术前CRP相似，移植术后的CRP也具有预测预后价值。Kornberg等人 [<xref ref-type="bibr" rid="hanspub.29240-ref59">59</xref>] 回顾性分析了106例HCC肝移植受者，指出术后早期CRP峰值是肝移植术后复发的重要指标，术后早期CRP峰值(&gt;3.5 mg/dL)的术后复发率为48.7%，而术后早期CRP峰值 ≤ 3.5 mg/dL的复发率仅为7.8%，同样的，这对米兰标准以外的患者意义更大。</p></sec><sec id="s6_2"><title>4.2. 中性粒细胞淋巴细胞比值(Neutrophil Lymphocyte Ratio, NLR)</title><p>中性粒细胞淋巴细胞比值是指外周血中性粒细胞与淋巴细胞的比值，已经被证实在多种恶性肿瘤预后预测中扮演重要作用。升高的NLR意味着炎症或外周淋巴细胞减少导致的中性白细胞增多，这两者都与恶性肿瘤的不良预后有关。Halazun等人 [<xref ref-type="bibr" rid="hanspub.29240-ref60">60</xref>] 首次将NLR与肝癌联系起来，分析了接受结直肠癌肝转移切除术的患者，并指出NLR升高与复发和死亡风险增加有关。</p><p>NLR在肝癌肝移植患者中已被广泛研究，Halazun等人 [<xref ref-type="bibr" rid="hanspub.29240-ref61">61</xref>] 首先将NLR应用于肝癌肝移植患者，在150例肝癌肝移植患者中，有13例患者NLR升高(≥5)，其中62% HCC复发，且5年生存率(28% vs 64%)和5年无瘤生存率(25% vs 75%)明显更差。另一项针对152例活体肝癌肝移植的研究指出NLR升高使肝细胞肝癌复发可能性增加7倍，并且在该队列中NLR比AFP更具预测性 [<xref ref-type="bibr" rid="hanspub.29240-ref62">62</xref>]。另一项针对涉及865例患者的大型研究指出，随着NLR增加每个对数单位，HCC复发的风险几乎翻了一番 [<xref ref-type="bibr" rid="hanspub.29240-ref7">7</xref>]。NLR已被认定为移植后HCC复发的独立危险因素，Najjar等人 [<xref ref-type="bibr" rid="hanspub.29240-ref63">63</xref>] 系统评价分析显示升高的NLR与移植后无瘤生存期相关。但关于NLR的最佳临界值尚未有定论，不同文献的临界值范围从2.6到6不等，Xu等人 [<xref ref-type="bibr" rid="hanspub.29240-ref64">64</xref>] 分析后建议将NLR最佳临界值指定为4。</p></sec><sec id="s6_3"><title>4.3. 血小板淋巴细胞比值(Platelet Lymphocyte Ratio, PLR)</title><p>血小板淋巴细胞比值是指外周血小板与淋巴细胞的比值，PLR对移植后HCC预后的意义研究不如NLR广泛。升高的PLR通常意味着更大的肿瘤大小，多发性肿瘤和血管侵犯 [<xref ref-type="bibr" rid="hanspub.29240-ref65">65</xref>]。2012年，Pinato等人首先将PLR应用于评估HCC患者移植预后评估，且分析得出PLR与NLR预测效果相当 [<xref ref-type="bibr" rid="hanspub.29240-ref66">66</xref>]。一项Meta分析 [<xref ref-type="bibr" rid="hanspub.29240-ref67">67</xref>] 指出高PLH与患者的术后HCC复发显著增加相关，但这项分析仅包括5项研究，899名患者，且具有中等异质性。Han等人 [<xref ref-type="bibr" rid="hanspub.29240-ref68">68</xref>] 也发现PLR与HCC移植后复发相关，但该研究支持血小板绝对计数与HCC移植后复发相关性更高。也有文章指出PLR未能预测符合米兰标准的患者的HCC复发 [<xref ref-type="bibr" rid="hanspub.29240-ref69">69</xref>]。虽然与NLR一样，PLR很容易获得，但其重要性有待研究，所以目前不推荐这项炎症标志物的广泛使用。</p></sec></sec><sec id="s7"><title>5. 总结与展望</title><p>尽管米兰标准等提出已经明显延长了HCC患者移植后的生存期，但移植后HCC复发仍明显影响患者术后生存率和生存质量。延伸和拓展米兰标准并结合相关分子标志物可以更安全地扩展移植受体范围，同时可以更好地预测移植后HCC复发，杭州标准就是一个典型的成功案例。本综述重点关注肿瘤标志物和炎症标志物与HCC移植术后的相关性，肿瘤标志物(包括AFP、DCP等)和炎症标志物(包括CRP、NLR、PLR等)均可以作为预测移植后HCC复发的分子标志物，但除AFP外，大部分标志物均未成功应用于临床。由于肿瘤的个体差异性较大，因此更多分子标志物组合使用可能更具临床意义。另外，目前大部分的研究都是回顾性研究，缺乏多中心前瞻性研究。未来需要更多的多中心前瞻性研究，以找着更合适的分子标志物组合，结合肿瘤形态学和病理学标准，更安全有效地筛选合适的HCC患者接受肝移植，实现预测复发风险，达到早期发现和治疗的目的，以获得更好的治疗效果。</p></sec><sec id="s8"><title>文章引用</title><p>章文燕,郑树森. 肝癌移植术后复发相关标志物的研究进展 Molecular Markers and Recurrence of Hepatocellular Carcinoma after Liver Transplantation[J]. 临床医学进展, 2019, 09(03): 310-318. https://doi.org/10.12677/ACM.2019.93047</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.29240-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.29240-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.</mixed-citation></ref><ref id="hanspub.29240-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版) [J]. 中华肝脏病杂志, 2017, 25(12): 886-895.</mixed-citation></ref><ref id="hanspub.29240-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Couri, T. and Pillai, A. (2019) Goals and Targets for Personalized Therapy for HCC. Hepatology International, 2, 1-13.  
&lt;br&gt;https://doi.org/10.1007/s12072-018-9919-1</mixed-citation></ref><ref id="hanspub.29240-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.Y. and Zheng, S.S. (2018) Advances in Predicting the Prognosis of Hepatocellular Carcinoma Recipients after Liver Transplantation. Journal of Zheijang University SCIENCE B, 19, 497-504.  
&lt;br&gt;https://doi.org/10.1631/jzus.B1700156</mixed-citation></ref><ref id="hanspub.29240-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Meirelles Junior, R.F., Salvalaggio, P., Rezende, M.B., et al. (2015) Liver Transplantation: History, Outcomes and Perspectives. Einstein (Sao Paulo), 13, 149-152. &lt;br&gt;https://doi.org/10.1590/S1679-45082015RW3164</mixed-citation></ref><ref id="hanspub.29240-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Agopian, V.G., Harlander-Locke, M., Zarrinpar, A., et al. (2015) A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Trans-plantation: Analysis of 865 Consecutive Liver Transplant Recipients. Journal of the American College of Surgeons, 220, 416-427.  
&lt;br&gt;https://doi.org/10.1016/j.jamcollsurg.2014.12.025</mixed-citation></ref><ref id="hanspub.29240-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chapman, W.C., Garcia-Aroz, S., Vachharajani, N., et al. (2017) Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging without Up-Front Stage Re-strictions. Journal of the American College of Surgeons, 224, 610-621. &lt;br&gt;https://doi.org/10.1016/j.jamcollsurg.2016.12.020</mixed-citation></ref><ref id="hanspub.29240-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rudnick, S.R. and Russo, M.W. (2018) Liver Transplan-tation beyond or Downstaging within the Milan Criteria for Hepatocellular Carcinoma. Expert Review of Gastroenter-ology &amp; Hepatology, 12, 265-275.  
&lt;br&gt;https://doi.org/10.1080/17474124.2018.1417035</mixed-citation></ref><ref id="hanspub.29240-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Akoad, M.E. and Pomfret, E.A. (2015) Surgical Resection and Liver Transplantation for Hepatocellular Carcinoma. Clinical Liver Disease, 19, 381-399. &lt;br&gt;https://doi.org/10.1016/j.cld.2015.01.007</mixed-citation></ref><ref id="hanspub.29240-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hirokawa, F., Hayashi, M., Miyamoto, Y., et al. (2015) Predictors of Poor Prognosis by Recurrence Patterns after Curative Hepatectomy for Hepatocellular Carcinoma in Child-Pugh Classification A. Hepatogastroenterology, 62, 164-168.</mixed-citation></ref><ref id="hanspub.29240-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Au, K.P. and Chok, K.S.H. (2018) Multidisciplinary Ap-proach for Post-Liver Transplant Recurrence of Hepatocellular Carcinoma: A Proposed Management Algorithm. World Journal of Gastroenterology, 24, 5081-5094.  
&lt;br&gt;https://doi.org/10.3748/wjg.v24.i45.5081</mixed-citation></ref><ref id="hanspub.29240-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Regalia, E., Fassati, L.R., Valente, U., et al. (1998) Pattern and Management of Recurrent Hepatocellular Carcinoma after Liver Transplantation. Journal of Hepato-Biliary-Pancreatic Surgery, 5, 29-34.  
&lt;br&gt;https://doi.org/10.1007/PL00009947</mixed-citation></ref><ref id="hanspub.29240-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Roayaie, S., Schwartz, J.D., Sung, M.W., et al. (2004) Recurrence of Hepatocellular Carcinoma after Liver Transplant: Patterns and Prognosis. Liver Transplantation, 10, 534-540. &lt;br&gt;https://doi.org/10.1002/lt.20128</mixed-citation></ref><ref id="hanspub.29240-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zimmerman, M.A., Ghobrial, R.M., Tong, M.J., et al. (2008) Recurrence of Hepatocellular Carcinoma Following Liver Transplantation: A Review of Preoperative and Postoperative Prognostic Indicators. Archives of Surgery, 143, 182-188; Discussion 188. &lt;br&gt;https://doi.org/10.1001/archsurg.2007.39</mixed-citation></ref><ref id="hanspub.29240-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">De’angelis, N., Landi, F., Carra, M.C., et al. (2015) Managements of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Systematic Review. World Journal of Gastro-enterology, 21, 11185-11198.  
&lt;br&gt;https://doi.org/10.3748/wjg.v21.i39.11185</mixed-citation></ref><ref id="hanspub.29240-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">关智芬, 陈伟强. 肝移植术后复发性肝细胞癌的多学科治疗[J]. 岭南现代临床外科, 2018, 18(5): 589-592.</mixed-citation></ref><ref id="hanspub.29240-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mazzaferro, V., Regalia, E., Doci, R., et al. (1996) Liver Trans-plantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. The New England Journal of Medicine, 334, 693-699.  
&lt;br&gt;https://doi.org/10.1056/NEJM199603143341104</mixed-citation></ref><ref id="hanspub.29240-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Yao, F.Y., Ferrell, L., Bass, N.M., et al. (2001) Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival. Hepatology, 33, 1394-1403.  
&lt;br&gt;https://doi.org/10.1053/jhep.2001.24563</mixed-citation></ref><ref id="hanspub.29240-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, S.S., Xu, X., Wu, J., et al. (2008) Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences. Transplantation, 85, 1726-1732. &lt;br&gt;https://doi.org/10.1097/TP.0b013e31816b67e4</mixed-citation></ref><ref id="hanspub.29240-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Marsh, J.W., Dvorchik, I., Bonham, C.A., et al. (2000) Is the Pathologic TNM Staging System for Patients with Hepatoma Predictive of Outcome. Cancer, 88, 538-543.  
&lt;br&gt;https://doi.org/10.1002/(SICI)1097-0142(20000201)88:3&lt;538::AID-CNCR7&gt;3.0.CO;2-H</mixed-citation></ref><ref id="hanspub.29240-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Jonas, S., Mittler, J., Pascher, A., et al. (2007) Living Donor Liver Transplantation of the Right Lobe for Hepatocellular Carcinoma in Cirrhosis in a European Center. Liver Transplantation, 13, 896-903. &lt;br&gt;https://doi.org/10.1002/lt.21189</mixed-citation></ref><ref id="hanspub.29240-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sugawara, Y., Tamura, S. and Makuuchi, M. (2007) Living Donor Liver Transplantation for Hepatocellular Carcinoma: Tokyo University Series. Digestive Diseases, 25, 310-312. &lt;br&gt;https://doi.org/10.1159/000106910</mixed-citation></ref><ref id="hanspub.29240-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S.G., Hwang, S., Moon, D.B., et al. (2008) Expanded Indication Criteria of Living Donor Liver Transplantation for Hepatocellular Carcinoma at One Large-Volume Center. Liver Transplantation, 14, 935-945.  
&lt;br&gt;https://doi.org/10.1002/lt.21445</mixed-citation></ref><ref id="hanspub.29240-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mazzaferro, V., Llovet, J.M., Miceli, R., et al. (2009) Predicting Survival after Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Retrospective, Exploratory Analysis. The Lancet Oncology, 10, 35-43. &lt;br&gt;https://doi.org/10.1016/S1470-2045(08)70284-5</mixed-citation></ref><ref id="hanspub.29240-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Fan, J., Yang, G.S., Fu, Z.R., et al. (2009) Liver Transplantation Outcomes in 1,078 Hepatocellular Carcinoma Patients: A Multi-Center Experience in Shanghai, China. Journal of Cancer Research and Clinical Oncology, 135, 1403-1412.  
&lt;br&gt;https://doi.org/10.1007/s00432-009-0584-6</mixed-citation></ref><ref id="hanspub.29240-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Yan, L.N., Yang, J., et al. (2009) Indicators of Prognosis after Liver Transplantation in Chinese Hepatocellular Carcinoma Patients. World Journal of Gastroenterology, 15, 4170-4176. &lt;br&gt;https://doi.org/10.3748/wjg.15.4170</mixed-citation></ref><ref id="hanspub.29240-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J.H., Sinn, D.H., Gwak, G.Y., et al. (2016) Factors Determining Long-Term Outcomes of Hepatocellular Carcinoma within the Milan Criteria: Liver Transplantation versus Locoregional Therapy: A Retrospective Cohort Study. Medicine (Baltimore), 95, e4735. &lt;br&gt;https://doi.org/10.1097/MD.0000000000004735</mixed-citation></ref><ref id="hanspub.29240-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Yao, F.Y., Mehta, N., Flemming, J., et al. (2015) Down-staging of Hepatocellular Cancer before Liver Transplant: Long-Term Outcome Compared to Tumors within Milan Criteria. Hepatology, 61, 1968-1977.  
&lt;br&gt;https://doi.org/10.1002/hep.27752</mixed-citation></ref><ref id="hanspub.29240-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Xu, X., Lu, D., Ling, Q., et al. (2016) Liver Transplantation for Hepato-cellular Carcinoma beyond the Milan Criteria. Gut, 65, 1035-1041. &lt;br&gt;https://doi.org/10.1136/gutjnl-2014-308513</mixed-citation></ref><ref id="hanspub.29240-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Levi Sandri, G.B., Rayar, M., Qi, X., et al. (2018) Liver Trans-plant for Patients outside Milan Criteria. Translational Gastroenterology and Hepatology, 3, 81. &lt;br&gt;https://doi.org/10.21037/tgh.2018.10.03</mixed-citation></ref><ref id="hanspub.29240-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Shimamura, T., Akamatsu, N., et al. (2018) Expanded Living-Donor Liver Transplantation Criteria for Patients with Hepatocellular Carcinoma Based on the Japanese Nationwide Survey: The 5-5-500 Rule—A Retrospective Study. Transplant International.</mixed-citation></ref><ref id="hanspub.29240-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J., Xu, X., Wu, J., et al. (2014) The Stratifying Value of Hangzhou Criteria in Liver Transplantation for Hepatocellular Carcinoma. PLoS ONE, 9, e93128. &lt;br&gt;https://doi.org/10.1371/journal.pone.0093128</mixed-citation></ref><ref id="hanspub.29240-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Qu, Z., Ling, Q., Gwiasda, J., et al. (2018) Hangzhou Criteria Are More Accurate than Milan Criteria in Predicting Long-Term Survival after Liver Transplantation for HCC in Germany. Langenbeck’s Archives of Surgery, 403, 643-654. &lt;br&gt;https://doi.org/10.1007/s00423-018-1696-8</mixed-citation></ref><ref id="hanspub.29240-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Audet, M., Panaro, F., Piardi, T., et al. (2009) Are the Hangzhou Criteria Adaptable to Hepatocellular Carcinoma Patients for Liver Transplantation in Western Countries? Liver Trans-plantation, 15, 822-823.  
&lt;br&gt;https://doi.org/10.1002/lt.21765</mixed-citation></ref><ref id="hanspub.29240-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Fan, S.T. (2008) Selection of HCC Patients for Liver Transplantation: The Milan Criteria, Hangzhou Criteria and beyond. Hepatobiliary &amp; Pancreatic Diseases International, 7, 233-234.</mixed-citation></ref><ref id="hanspub.29240-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Duvoux, C., Roudot-Thoraval, F., Decaens, T., et al. (2012) Liver Transplantation for Hepatocellular Carcinoma: A Model Including Alpha-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology, 143, 986-994.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2012.05.052</mixed-citation></ref><ref id="hanspub.29240-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Toso, C., Asthana, S., Bigam, D.L., et al. (2009) Reassessing Selection Criteria Prior to Liver Transplantation for Hepatocellular Carcinoma Utilizing the Scientific Registry of Transplant Recipients Database. Hepatology, 49, 832-838.  
&lt;br&gt;https://doi.org/10.1002/hep.22693</mixed-citation></ref><ref id="hanspub.29240-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Toso, C., Meeberg, G., Hernandez-Alejandro, R., et al. (2015) Total Tumor Volume and Alpha-Fetoprotein for Selection of Transplant Candidates with Hepatocellular Carcinoma: A Prospective Validation. Hepatology, 62, 158-165.  
&lt;br&gt;https://doi.org/10.1002/hep.27787</mixed-citation></ref><ref id="hanspub.29240-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Han, K., Tzimas, G.N., Barkun, J.S., et al. (2007) Preoperative Alpha-Fetoprotein Slope Is Predictive of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Canadian Journal of Gastroenterology, 21, 39-45.  
&lt;br&gt;https://doi.org/10.1155/2007/206383</mixed-citation></ref><ref id="hanspub.29240-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Dumitra, T.C., Dumitra, S., Metrakos, P.P., et al. (2013) Pretransplantation Alpha-Fetoprotein Slope and Milan Criteria: Strong Predictors of Hepatocellular Carcinoma Recurrence after Transplantation. Transplantation, 95, 228-233.  
&lt;br&gt;https://doi.org/10.1097/TP.0b013e31827743d7</mixed-citation></ref><ref id="hanspub.29240-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Citores, M.J., Lucena, J.L., De La Fuente, S., et al. (2019) Serum Biomarkers and Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. World Journal of Hepatology, 11, 50-64. &lt;br&gt;https://doi.org/10.4254/wjh.v11.i1.50</mixed-citation></ref><ref id="hanspub.29240-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Yang, N., Li, Z., Yan, M., et al. (2019) Evaluation of Serum Alpha-Fetoprotein Level in Chronic Hepatitis C Patients. Clinical Laboratory, 65.</mixed-citation></ref><ref id="hanspub.29240-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Schieving, J.H., De Vries, M., Van Vugt, J.M., et al. (2014) Alpha-Fetoprotein, a Fascinating Protein and Biomarker in Neurology. European Journal of Paediatric Neurology, 18, 243-248. &lt;br&gt;https://doi.org/10.1016/j.ejpn.2013.09.003</mixed-citation></ref><ref id="hanspub.29240-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022.  
&lt;br&gt;https://doi.org/10.1002/hep.24199</mixed-citation></ref><ref id="hanspub.29240-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 4, 908-943.</mixed-citation></ref><ref id="hanspub.29240-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Benson, A.B., D’angelica, M.I., Abrams, T.A., et al. (2014) Hepatobiliary Cancers, Version 2.2014. Journal of the National Comprehensive Cancer Network, 12, 1152-1182. &lt;br&gt;https://doi.org/10.6004/jnccn.2014.0112</mixed-citation></ref><ref id="hanspub.29240-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Chaiteerakij, R., Zhang, X., Addissie, B.D., et al. (2015) Combinations of Biomarkers and Milan Criteria for Predicting Hepatocellular Carcinoma Recurrence after Liver Transplantation. Liver Transplantation, 21, 599-606.  
&lt;br&gt;https://doi.org/10.1002/lt.24117</mixed-citation></ref><ref id="hanspub.29240-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Pote, N., Cauchy, F., Albuquerque, M., et al. (2015) Performance of PIVKA-II for Early Hepatocellular Carcinoma Diagnosis and Prediction of Microvascular Invasion. Journal of Hepatology, 62, 848-854.  
&lt;br&gt;https://doi.org/10.1016/j.jhep.2014.11.005</mixed-citation></ref><ref id="hanspub.29240-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Hong, Y.M., Cho, M., Yoon, K.T., et al. (2017) Risk Factors of Early Recurrence after Curative Hepatectomy in Hepatocellular Carcinoma. Tumor Biology, 39, 1010428317720863. &lt;br&gt;https://doi.org/10.1177/1010428317720863</mixed-citation></ref><ref id="hanspub.29240-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Takada, Y., Ito, T., Ueda, M., et al. (2007) Living Donor Liver Transplantation for Patients with HCC Exceeding the Milan Criteria: A Proposal of Expanded Criteria. Digestive Diseases, 25, 299-302. &lt;br&gt;https://doi.org/10.1159/000106908</mixed-citation></ref><ref id="hanspub.29240-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Yang, K., Lee, T.B., Choi, B.H., et al. (2016) Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma. Transplantation Proceedings, 48, 3317-3322.  
&lt;br&gt;https://doi.org/10.1016/j.transproceed.2016.08.050</mixed-citation></ref><ref id="hanspub.29240-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.H., Moon, D.B., Kim, W.J., et al. (2016) Preoperative Prognostic Values of Alpha-Fetoprotein (AFP) and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) in Patients with Hepatocellular Carcinoma for Living Donor Liver Transplantation. Hepatobiliary Surgery and Nutrition, 5, 461-469.  
&lt;br&gt;https://doi.org/10.21037/hbsn.2016.11.05</mixed-citation></ref><ref id="hanspub.29240-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">De Stefano, F., Chacon, E., Turcios, L., et al. (2018) Novel Biomarkers in Hepatocellular Carcinoma. Digestive and Liver Disease, 50, 1115-1123. &lt;br&gt;https://doi.org/10.1016/j.dld.2018.08.019</mixed-citation></ref><ref id="hanspub.29240-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Kulik, L. and El-Serag, H.B. (2019) Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 156, 477-491.e471. &lt;br&gt;https://doi.org/10.1053/j.gastro.2018.08.065</mixed-citation></ref><ref id="hanspub.29240-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Kinoshita, A., Onoda, H., Imai, N., et al. (2015) C-Reactive Protein as a Prognostic Marker in Patients with Hepatocellular Carcinoma. Hepatogastroenterology, 62, 966-970.</mixed-citation></ref><ref id="hanspub.29240-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Chan, S.L. and Chan, A.W. (2017) Systematic Evaluation of Circulating Inflammatory Markers for Hepatocellular Carcinoma. Liver International, 37, 280-289.</mixed-citation></ref><ref id="hanspub.29240-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">An, H.J., Jang, J.W., Bae, S.H., et al. (2012) Serum C-Reactive Protein Is a Useful Biomarker for Predicting Outcomes after Liver Transplantation in Patients with Hepatocellular Carcinoma. Liver Transplantation, 18, 1406-1414.  
&lt;br&gt;https://doi.org/10.1002/lt.23512</mixed-citation></ref><ref id="hanspub.29240-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Kornberg, A., Witt, U., Kornberg, J., et al. (2016) Postoperative Peak Serum C-Reactive Protein Is a Predictor of Outcome Following Liver Transplantation for Hepatocellular Carcinoma. Biomarkers, 21, 152-159.  
&lt;br&gt;https://doi.org/10.3109/1354750X.2015.1118548</mixed-citation></ref><ref id="hanspub.29240-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Halazun, K.J., Aldoori, A., Malik, H.Z., et al. (2008) Elevated Preoperative Neutrophil to Lymphocyte Ratio Predicts Survival Following Hepatic Resection for Colorectal Liver Metastases. European Journal of Surgical Oncology, 34, 55-60. &lt;br&gt;https://doi.org/10.1016/j.ejso.2007.02.014</mixed-citation></ref><ref id="hanspub.29240-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Halazun, K.J., Hardy, M.A., Rana, A.A., et al. (2009) Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome after Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgery, 250, 141-151.  
&lt;br&gt;https://doi.org/10.1097/SLA.0b013e3181a77e59</mixed-citation></ref><ref id="hanspub.29240-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Yoshizumi, T., Ikegami, T., Yoshiya, S., et al. (2013) Impact of Tumor Size, Number of Tumors and Neutrophil-to-Lymphocyte Ratio in Liver Transplantation for Recurrent Hepatocellular Carcinoma. Hepatology Research, 43, 709-716. &lt;br&gt;https://doi.org/10.1111/hepr.12016</mixed-citation></ref><ref id="hanspub.29240-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Najjar, M., Agrawal, S., Emond, J.C., et al. (2018) Pretreatment Neutrophil-Lymphocyte Ratio: Useful Prognostic Biomarker in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 5, 17-28.  
&lt;br&gt;https://doi.org/10.2147/JHC.S86792</mixed-citation></ref><ref id="hanspub.29240-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Xu, Z.G., Ye, C.J., Liu, L.X., et al. (2018) The Pretransplant Neutrophil-Lymphocyte Ratio as a New Prognostic Predictor after Liver Transplantation for Hepatocellular Cancer: A Systematic Review and Meta-Analysis. Biomarkers in Medicine, 12, 189-199. &lt;br&gt;https://doi.org/10.2217/bmm-2017-0307</mixed-citation></ref><ref id="hanspub.29240-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Xia, W., Ke, Q., Wang, Y., et al. (2015) Predictive Value of Pre-Transplant Platelet to Lymphocyte Ratio for Hepatocellular Carcinoma Recurrence after Liver Transplantation. World Journal of Surgical Oncology, 13, 60.  
&lt;br&gt;https://doi.org/10.1186/s12957-015-0472-2</mixed-citation></ref><ref id="hanspub.29240-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Pinato, D.J., Stebbing, J., Ishizuka, M., et al. (2012) A Novel and Validated Prognostic Index in Hepatocellular Carcinoma: The Inflammation Based Index (IBI). Journal of Hepatology, 57, 1013-1020.  
&lt;br&gt;https://doi.org/10.1016/j.jhep.2012.06.022</mixed-citation></ref><ref id="hanspub.29240-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Lai, Q., Melandro, F., Larghi Laureiro, Z., et al. (2018) Platelet-to-Lymphocyte Ratio in the Setting of Liver Transplantation for Hepatocellular Cancer: A Systematic Review and Meta-Analysis. World Journal of Gastroenterology, 24, 1658-1665. &lt;br&gt;https://doi.org/10.3748/wjg.v24.i15.1658</mixed-citation></ref><ref id="hanspub.29240-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Han, S., Lee, S., Yang, J.D., et al. (2018) Risk of Posttransplant Hepatocellular Carcinoma Recurrence Is Greater in Recipients with Higher Platelet Counts in Living Donor Liver Transplantation. Liver Transplantation, 24, 44-55.  
&lt;br&gt;https://doi.org/10.1002/lt.24961</mixed-citation></ref><ref id="hanspub.29240-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Xia, W., Ke, Q., Guo, H., et al. (2017) Expansion of the Milan Criteria without Any Sacrifice: Combination of the Hangzhou Criteria with the Pre-Transplant Platelet-to-Lymphocyte Ratio. BMC Cancer, 17, 14.  
&lt;br&gt;https://doi.org/10.1186/s12885-016-3028-0</mixed-citation></ref></ref-list></back></article>